Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Exploiting dendritic cells to improve vaccine efficacy
Ralph M. Steinman, Melissa Pope
Ralph M. Steinman, Melissa Pope
Published June 15, 2002
Citation Information: J Clin Invest. 2002;109(12):1519-1526. https://doi.org/10.1172/JCI15962.
View: Text | PDF
Perspective

Exploiting dendritic cells to improve vaccine efficacy

  • Text
  • PDF
Abstract

Authors

Ralph M. Steinman, Melissa Pope

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Some specializations of DCs for vaccine capture, MHC-peptide complex for...
Some specializations of DCs for vaccine capture, MHC-peptide complex formation, and T cell stimulation. DCs express many adsorptive uptake receptors whose natural ligands are generally not yet known. For this reason, anti-receptor antibodies are often used experimentally as surrogate antigens. Several receptors are type II transmembrane proteins with a single external C-type lectin domain found on distinct DC subsets: DC-SIGN and the asialoglycoprotein receptor on monocyte-derived DCs, BDCA-2 on plasmacytoid cells, and Langerin on Langerhans cells. MMR and DEC-205 are type I proteins with eight to ten contiguous C-type lectin domains; these receptors can also be expressed on certain endothelia and epithelia. Other receptors, such as FcγR, are not DC-restricted but function selectively in DCs to mediate the exogenous pathway for presentation on MHC class I products. Beyond antigen capture, DCs (or particular DC subsets) express high levels of select TLRs and thereby mature in response to specific microbial stimuli. During maturation, DCs produce and export high levels of several costimulatory molecules for T cell growth and differentiation. DC maturation regulates many of the elements involved in antigen capture and processing.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts